Eszopiclone
Lunesta (eszopiclone) is a small molecule pharmaceutical. Eszopiclone was first approved as Lunesta on 2004-12-15. It is used to treat sleep initiation and maintenance disorders in the USA.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
Lunesta (generic drugs available since 2011-05-23)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Eszopiclone
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| LUNESTA | Woodward Pharma Services | N-021476 RX | 2004-12-15 | 3 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| eszopiclone | ANDA | 2023-04-26 |
| lunesta | New Drug Application | 2021-09-13 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
65 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Sleep initiation and maintenance disorders | D007319 | F51.01 | 2 | 2 | 16 | 16 | 9 | 43 | |
| Obstructive sleep apnea | D020181 | EFO_0003918 | G47.33 | 2 | 4 | — | 2 | 1 | 8 |
| Healthy volunteers/patients | — | 2 | — | 1 | 1 | — | 4 | ||
| Major depressive disorder | D003865 | EFO_0003761 | F22 | — | — | 2 | 1 | — | 3 |
| Sleep wake disorders | D012893 | G47 | — | 1 | — | 1 | 1 | 3 | |
| Sleep | D012890 | GO_0030431 | — | 1 | — | 1 | — | 2 | |
| Post-traumatic stress disorders | D013313 | EFO_0001358 | F43.1 | — | — | — | 2 | — | 2 |
| Depression | D003863 | F33.9 | — | — | — | 2 | — | 2 | |
| Anxiety disorders | D001008 | EFO_0006788 | F41.1 | — | 1 | — | 1 | — | 2 |
| Tobacco use disorder | D014029 | F17 | — | — | — | 1 | — | 1 |
Show 5 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Attention deficit disorder with hyperactivity | D001289 | EFO_0003888 | F90 | — | — | 2 | — | — | 2 |
| Rheumatoid arthritis | D001172 | EFO_0000685 | M06.9 | — | — | 1 | — | — | 1 |
| Parkinson disease | D010300 | EFO_0002508 | G20 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Sleep apnea syndromes | D012891 | EFO_0003877 | G47.3 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Prediabetic state | D011236 | EFO_1001121 | R73.03 | 1 | — | — | — | — | 1 |
| Glucose intolerance | D018149 | HP_0000833 | R73.03 | 1 | — | — | — | — | 1 |
| Marijuana abuse | D002189 | EFO_0007191 | F12 | 1 | — | — | — | — | 1 |
| Therapeutic equivalency | D013810 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Schizophrenia | D012559 | EFO_0000692 | F20 | — | — | — | — | 3 | 3 |
| Circadian rhythm sleep disorders | D020178 | G47.2 | — | — | — | — | 1 | 1 | |
| Psychotic disorders | D011618 | F20.81 | — | — | — | — | 1 | 1 | |
| Fatigue | D005221 | HP_0012378 | R53.83 | — | — | — | — | 1 | 1 |
| Relapsing-remitting multiple sclerosis | D020529 | EFO_0003929 | — | — | — | — | 1 | 1 | |
| Osteoarthritis | D010003 | EFO_0002506 | M15-M19 | — | — | — | — | 1 | 1 |
| Menopause | D008593 | EFO_0003922 | N95 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | ESZOPICLONE |
| INN | eszopiclone |
| Description | Eszopiclone is the (5S)- (active) enantiomer of zopiclone. Unlike almost all other hypnotic sedatives, which are approved only for the relief of short-term (6-8 weeks) insomnia, eszopiclone is approved by the U.S. Food and Drug Administration for long-term use. It has a role as a sedative and a central nervous system depressant. It is an enantiomer of a (5R)-zopiclone. |
| Classification | Small molecule |
| Drug class | hypnotics/tranquilizers (zopiclone type) |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CN1CCN(C(=O)O[C@H]2c3nccnc3C(=O)N2c2ccc(Cl)cn2)CC1 |
Identifiers
| PDB | — |
| CAS-ID | 138729-47-2 |
| RxCUI | 461016 |
| ChEMBL ID | CHEMBL1522 |
| ChEBI ID | 53760 |
| PubChem CID | 969472 |
| DrugBank | DB00402 |
| UNII ID | UZX80K71OE (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,725 documents
View more details
Safety
Black-box Warning
Black-box warning for: Eszopiclone, Lunesta
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
22,236 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more